Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD
  • Regulatory

S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD

OncLive Podcast

Welcome to OncLive On Air !

RegulatoryOncologyRead full story

pharminent March 31, 2026 (Last updated: April 1, 2026)

OncLive Podcast

Welcome to OncLive On Air !

RegulatoryOncologyRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Novo hits back at rivals with cut-price Wegovy subscriptions
Next: NHS to offer Wegovy to a million more people in England

Related Stories

  • Regulatory

Outlook Therapeutics Secures FDA Approval for LYTENAVA

pharminent July 31, 2026
  • Regulatory

Outlook finally claims FDA approval for AMD drug

pharminent July 27, 2026
  • Regulatory

Outlook Therapeutics wins FDA approval for Lytenava in wet AMD

pharminent July 27, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.